Incyte (NASDAQ:INCY) will post its quarterly earnings results before the market opens on Thursday, February 15th. Analysts expect Incyte to post earnings of $0.01 per share for the quarter.
Shares of Incyte (NASDAQ INCY) opened at $86.34 on Thursday. The firm has a market cap of $18,220.00, a PE ratio of -107.93 and a beta of 0.59. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.81 and a current ratio of 4.82. Incyte has a 12 month low of $84.21 and a 12 month high of $153.15.
In other Incyte news, Director Paul A. Friedman sold 28,507 shares of Incyte stock in a transaction that occurred on Thursday, November 16th. The shares were sold at an average price of $105.24, for a total transaction of $3,000,076.68. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Vijay K. Iyengar sold 5,000 shares of Incyte stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $97.26, for a total transaction of $486,300.00. The disclosure for this sale can be found here. Insiders have sold 40,963 shares of company stock worth $4,222,953 in the last ninety days. Insiders own 17.70% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Incyte (INCY) Scheduled to Post Earnings on Thursday” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://www.com-unik.info/2018/02/08/incyte-incy-scheduled-to-post-earnings-on-thursday.html.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.